25th Jun 2019 16:47
Director/PDMR Dealings
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name | James Barder | ||||
2 | Reason for the notification | |||||
a) | Position/status | Chief Executive Officer | ||||
b) | Initial notification/Amendment | Amendment - additional disclosure to the Director Dealing announcement dated 19 November 2018 clarifying a voluntary surrender of options. All other details were and remain correct. | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Futura Medical plc | ||||
b) | LEI | 21380053QLT46UNV2303 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary Shares of 0.2 pence each
GB0033278473 | ||||
b) | Nature of the transaction | Surrender of options over ordinary shares | ||||
c) | Price(s) and volume(s)
|
| ||||
d) | Aggregated information - Aggregated volume - Price | N/A | ||||
e) | Date of the transaction | 16th November 2018 | ||||
f) | Place of the transaction | Outside a trading venue | ||||
For further information please contact:
Futura Medical plc James Barder, Chief ExecutiveAngela Hildreth, Finance Director and COOEmail: Investor.relations@futuramedical.comTel: +44 (0) 1483 685 670
Liberum (Nominated Adviser and Broker)Bidhi BhomaEuan BrownKane CollingsTel: +44 (0) 20 3100 2000
For media enquiries please contact:Optimum Strategic CommunicationsMary Clark/ Hollie Vile/ Ellie BlackwellEmail: futuramedical@optimumcomms.comTel: +44 (0) 203 950 9144
Notes to editors:
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com
Related Shares:
Futura Medical